Novo Nordisk Pins Hopes on CagriSema Data and Wegovy Combo Study to Reverse Stock’s Slide
Novo Nordisk unveils first Phase 3 CagriSema diabetes results at ADA, launches Wegovy combo trial with Veru, as…
Novo Nordisk’s New Orleans Moment: Can CagriSema Data Reverse a 44% Slide?
Novo Nordisk’s 44% stock slide faces pivotal ADA test: Phase 3 CagriSema data for diabetes/obesity could restore confidence…
Novo Nordisk’s Pipeline Showdown: Can CagriSema and Zenagamtide Reverse the Stock’s Slide?
Novo Nordisk unveils CagriSema Phase 3 data at ADA after stock drop; oral Wegovy pill shows strong early…
Novo Nordisk Bets on AI and New Products to Reverse Steep Share Slide
Novo Nordisk shares rebound on UK Wegovy pen approval. The firm combats a weak outlook with an OpenAI…